Effects of Ocrevus in Relapsing Multiple Sclerosis
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test if people with relapsing multiple sclerosis (RMS) can
improve ambulatory functions after one-year treatment with Ocrevus in comparison with
platform therapy. Sixty qualified individuals with RMS will be evenly assigned into two
groups: Ocrevus and Platform. Each group will receive the respective treatment following the
FDA regulations over the one-year course. Their ambulatory functions will be assessed five
times three months apart. In addition, they will receive brain MRI scans three times six
months apart. Their ambulatory functions and MRI measurements will be compared between groups
over time to fulfill the purposes of this study.